Artelo Biosciences gets USPTO notice of allowance for ART27.13 formulation patent application
ARTL•USPTO allowance for ART27.13 formulation patent
- Artelo Biosciences received a USPTO Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13.
- Claims cover ART27.13 compositions dispersed in polyethylene glycol; patent protection is expected to run through 2041.
- ART27.13 is being tested in two Phase 2 studies, including CAReS for cancer-related anorexia and DREAM for glaucoma or ocular hypertension.
